Ryan E. Ferguson

Dr. Ryan E. Ferguson


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
AIAreef Ishani
Areef Ishani
WCWilliam C. Cushman
William C. Cushman
SLSarah M. Leatherman
Sarah M. Leatherman
RLRobert A. Lew
Robert A. Lew
PWPatricia Woods
Patricia Woods
RFRyan E. Ferguson
Ryan E. Ferguson
Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiovascular events in patients with hypertension is unclear.

17 December 2019 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
JRJohn E Ripollone
John E Ripollone
KHKrista F Huybrechts
Krista F Huybrechts
KRKenneth J Rothman
Kenneth J Rothman
RFRyan E. Ferguson
Ryan E. Ferguson
JFJessica M Franklin
Jessica M Franklin
Coarsened exact matching (CEM) is a matching method proposed as an alternative to other techniques commonly used to control confounding. We compared CEM with 3 techniques that have been used in pharmacoepidemiology: propensity score matching, Mahalanobis distance matching, and fine stratification by propensity score (FS). We evaluated confounding control and effect-estimate precision using insurance claims data from the Pharmaceutical Assistance Contract for the Elderly (1999–2002) and Medicaid Analytic eXtract (2000–2007) databases (United States) and from simulated claims-based cohorts. CEM generally achieved the best covariate balance. However, it often led to high bias and low precision of the risk ratio due to extreme losses in study size and numbers of outcomes (i.e., sparse data bias)—especially with larger covariate sets. FS usually was optimal with respect to bias and precision and always created good covariate balance. Propensity score matching usually performed almost as well as FS, especially with higher index exposure prevalence. The performance of Mahalanobis distance matching was relatively poor. These findings suggest that CEM, although it achieves good covariate balance, might not be optimal for large claims-database studies with rich covariate information; it might be ideal if only a few (<10) strong confounders must be controlled.

8 April 2011 in Clinical Trials
Verified
Journal Article
Open access
LFLouis D Fiore
Louis D Fiore
MBMary Brophy
Mary Brophy
RFRyan E. Ferguson
Ryan E. Ferguson
LDLeonard D’aVolio
Leonard D’aVolio
JHJohn A Hermos
John A Hermos
PLPhilip W Lavori
Philip W Lavori
Background Clinical trials are widely considered the gold standard in comparative effectiveness research (CER) but the high cost and complexity of traditional trials and concerns about generalizability to broad patient populations and general clinical practice limit their appeal. Unsuccessful implementation of CER results limits the value of even the highest quality trials. Planning for a trial comparing two standard strategies of insulin administration for hospitalized patients led us to develop a new method for a clinical trial designed to be embedded directly into the clinical care setting thereby lowering the cost, increasing the pragmatic nature of the overall trial, strengthening implementation, and creating an integrated environment of research-based care. Purpose We describe a novel randomized clinical trial that uses the informatics and statistics infrastructure of the Veterans Affairs Healthcare System (VA) to illustrate one key component (called the point-of-care clinical trial – POC-CT) of a ‘learning healthcare system,’ and settles a clinical question of interest to the VA. Methods This study is an open-label, randomized trial comparing sliding scale regular insulin to a weight-based regimen for control of hyperglycemia, using the primary outcome length of stay, in non-ICU inpatients within the northeast region of the VA. All non-ICU patients who require in-hospital insulin therapy are eligible for the trial, and the VA’s automated systems will be used to assess eligibility and present the possibility of randomization to the clinician at the point of care. Clinicians will indicate their approval for informed consent to be obtained by study staff. Adaptive randomization will assign up to 3000 patients, preferentially to the currently ‘winning’ strategy, and all care will proceed according to usual practices. Based on a Bayesian stopping rule, the study has acceptable frequentist operating characteristics (Type I error 6%, power 86%) against a 12% reduction of median length of stay from 5 to 4.4 days. The adaptive stopping rule promotes implementation of a successful treatment strategy. Limitations Despite clinical equipoise, individual healthcare providers may have strong treatment preferences that jeopardize the success and implementation of the trial design, leading to low rates of randomization. Unblinded treatment assignment may bias results. In addition, generalization of clinical results to other healthcare systems may be limited by differences in patient population. Generalizability of the POC-CT method depends on the level of informatics and statistics infrastructure available to a healthcare system. Conclusions The methods proposed will demonstrate outcome-based evaluation of control of hyperglycemia in hospitalized veterans. By institutionalizing a process of statistically sound and efficient learning, and by integrating that learning with automatic implementation of best practice, the participating VA Healthcare Systems will accelerate improvements in the effectiveness of care.

17 November 2021 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
IKIra R. Katz
Ira R. Katz
MRMalcolm P. Rogers
Malcolm P. Rogers
RLRobert Lew
Robert Lew
STSoe Soe Thwin
Soe Soe Thwin
GDGheorghe Doros
Gheorghe Doros
DYDeborah Yurgelun-Todd
Deborah Yurgelun-Todd
Suicide is a devastating clinical and public health problem. In 2017, suicide was the nation’s 10th leading cause of death.1 Up to 90% of suicides are attributable to mental illness2-4 and more than 20% to diagnosed affective disorders.5 Veterans accounted for 13% of all US deaths from suicide in 2017, with an age- and sex-adjusted rate for all veterans 1.5 times greater than other Americans.6 This increased risk led the US Department of Veterans Affairs (VA) to establish comprehensive programs, clinical services, and research to prevent suicide.6,7

1 June 2012 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
LDLeonard D'Avolio
Leonard D'Avolio
RFRyan E. Ferguson
Ryan E. Ferguson
SGSergey Goryachev
Sergey Goryachev
PWPatricia Woods
Patricia Woods
TSThomas Sabin
Thomas Sabin
LFLouis Fiore
Louis Fiore
Objectives The Massachusetts Veterans Epidemiology Research and Information Center in collaboration with the Stanford Center for Innovative Study Des

1 September 2021 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
PWPatricia Woods
Patricia Woods
MFMaura Flynn
Maura Flynn
PMPaul Monach
Paul Monach
KVKaren Visnaw
Karen Visnaw
SSSara Schiller
Sara Schiller
WBWestyn Branch-Elliman
Westyn Branch-Elliman
The communicable nature of many infectious diseases, including SARS-CoV-2, creates challenges for implementing and obtaining regulatory-compliant written informed consent. The goal of this project was to identify and evaluate processes that address these barriers while maintaining clinical and research staff safety. We reviewed Federal Drug Administration (FDA), World Health Organization (WHO), and VA Office of Research and Development (ORD) guidance about informed consent during the COVID-19 pandemic, and identified and pilot-tested several mechanisms for obtaining regulatory-compliant consent during our COVID-19 therapeutics clinical trial. Several processes were identified. These included a standard face-to-face consent with a plan for maintaining a paper copy of the signed consent form, a phone or video chat consent process that included taking a picture of the signed consent form or a screen shot of the signed document during a video chat, integration of the consent forms into software embedded within the electronic health record, and secure software programs with electronic signature. These processes are FDA-compliant but time-intensive, often requiring four or more hours of coordination between the clinical team, research staff, patients, and legally authorized representatives. Future studies could evaluate how to improve efficiency, and whether some elements of the consenting process, such as the requirement for documented written signed consent, rather than a witnessed oral consent, is an acceptable standard for research participants with communicable diseases.